-

Bristol Myers Squibb to Take Part in the Cowen Virtual 41st Annual Health Care Conference

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in a fireside chat at the Cowen Virtual 41st Annual Health Care Conference, which will be webcast on Wednesday, March 3, 2021. Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Global Drug Development will answer questions about the company at 10:20 a.m. ET.

Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. Material related to the company’s presentation will be available at the same website at the start of the live webcast. An archived edition of the session will be available later that day.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

CorporateFinancial-News

Contacts

Bristol Myers Squibb

Media:
media@bms.com

Investor Relations:
Tim Power, 609-252-7509, timothy.power@bms.com
Nina Goworek, 908-673-9711, nina.goworek@bms.com

Bristol Myers Squibb

NYSE:BMY

Release Summary
Bristol Myers Squibb to Take Part in the Cowen Virtual 41st Annual Health Care Conference
Release Versions

Contacts

Bristol Myers Squibb

Media:
media@bms.com

Investor Relations:
Tim Power, 609-252-7509, timothy.power@bms.com
Nina Goworek, 908-673-9711, nina.goworek@bms.com

More News From Bristol Myers Squibb

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

BOTHELL, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)--Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung......

Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study

BOTHELL, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)--Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2-......
Back to Newsroom